Exchange: NASDAQ·Updated 07:34 PM EDT
Upcoming Earnings: Q2 '26

Reports: Aug 06Pre-Market

Estimated EPS

-$1.16

Estimated Rev

$0M

$IMUX Q1 '26 Earnings Results & Recap Immunic expects to fund operations into late 2027 with $200M from a private placement, targeting NDA submission in mid-2027 and regulatory approval in 2028 for vidofludimus calcium.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$1.16
--
--
N/A
Q1 '26
-$0.69
-$1.08
-57.09%
MISSED
Q4 '25
-$0.09
--
--
N/A
Q3 '25
-$0.14
-$0.13
9.30%
BEAT
Q2 '25
-$0.16
-$0.20
-26.74%
MISSED

Advertisement|Remove ads.